• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Traws Pharma, Inc. - Common Stock (NQ:TRAW)

    0.6840 -0.0140 (-2.01%)
    Streaming Delayed Price Updated: 1:38 PM EDT, Jul 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 84,970
    Open 0.6850
    Bid (Size) 0.6840 (200)
    Ask (Size) 0.7088 (200)
    Prev. Close 0.6980
    Today's Range 0.6785 - 0.7200
    52wk Range 0.6400 - 3.265
    Shares Outstanding 5,564,315
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
    Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed 
    From Traws Pharma, Inc.
    Via GlobeNewswire
    Monday's session: top gainers and losers ↗
    Via Chartmill

    Performance

    YTD
    -48.6%
    -48.6%
    1 Month
    -50.1%
    -50.1%
    3 Month
    -57.2%
    -57.2%
    6 Month
    -47.4%
    -47.4%
    1 Year
    -52.8%
    -52.8%

    More News

    Read More
    Gapping stocks in Monday's session ↗
    Via Chartmill
    Monday's pre-market session: top gainers and losers ↗
    Via Chartmill
    TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗
    Via Stocktwits
    News headline image
    Traws Pharma Provides Regulatory Update on Influenza Program
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
    From Traws Pharma, Inc.
    Via GlobeNewswire
    Unusual volume stocks are being observed in Monday's session. ↗
    Via Chartmill
    Friday's session: top gainers and losers ↗
    Via Chartmill
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    Gapping stocks in Friday's session ↗
    Via Chartmill
    Which stocks are moving before the opening bell on Friday? ↗
    Via Chartmill
    News headline image
    Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    TRAWS PHARMA INC (NASDAQ:TRAW) Reports 2025 Earnings Beat Amid Dilutive $60M PIPE Financing and FDA Hold ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Traws Pharma Announces Up to $60 Million Private Placement Financing
    From Traws Pharma, Inc.
    Via GlobeNewswire
    Top stock movements in today's session. ↗
    Via Chartmill
    Gapping stocks in Thursday's session ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
    From Traws Pharma, Inc.
    Via GlobeNewswire
    Top movers analysis in the middle of the day on 2026-01-28: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
    From Traws Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill

    Frequently Asked Questions

    Is Traws Pharma, Inc. - Common Stock publicly traded?
    Yes, Traws Pharma, Inc. - Common Stock is publicly traded.
    What exchange does Traws Pharma, Inc. - Common Stock trade on?
    Traws Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Traws Pharma, Inc. - Common Stock?
    The ticker symbol for Traws Pharma, Inc. - Common Stock is TRAW on the Nasdaq Stock Market
    What is the current price of Traws Pharma, Inc. - Common Stock?
    The current price of Traws Pharma, Inc. - Common Stock is 0.6840
    When was Traws Pharma, Inc. - Common Stock last traded?
    The last trade of Traws Pharma, Inc. - Common Stock was at 07/08/26 01:38 PM ET
    What is the market capitalization of Traws Pharma, Inc. - Common Stock?
    The market capitalization of Traws Pharma, Inc. - Common Stock is 3.81M
    How many shares of Traws Pharma, Inc. - Common Stock are outstanding?
    Traws Pharma, Inc. - Common Stock has 4M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.